GSK

GSK will take full global rights to the experimental TCE programme in return for an upfront payment and potential development and commercial milestone payments.

The shift also comes as pharmaceutical companies invest in newer technologies that could change how influenza vaccines are developed and manufactured.

The deal also includes up to US$1.185 billion in development, regulatory and commercial milestone payments, bringing its potential total value to US$1.295 billion.

The antisense oligonucleotide (ASO) medicine, which GSK will market in Japan as Hibsago, is approved for adults with hepatitis B who meet specified viral markers.

The US Food and Drug Administration (FDA) approved Jideytro for adults with locally advanced or metastatic ROS1-positive NSCLC who have previously received treatment with a ROS1 kinase inhibitor.

The vaccine was registered earlier this month by the South African Health Products Regulatory Authority (SAHPRA), paving the way for large-scale importation and commercial distribution.

More than 3 million cases of complicated UTIs are recorded annually in the United States, and treatment failure affects up to one-third of patients.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

CTTQ will also purchase a supply of bepirovirsen for an initial period of five and a half years, while GSK will record product sales from the arrangement, though the companies are not disclosing the financial value of the deal.